Literature DB >> 17658958

Community pharmacy-based hypertension disease-management program in a Latino/Hispanic-American population.

L Leanne Lai1.   

Abstract

OBJECTIVE: To evaluate if the community, pharmacy-based hypertension disease-management (DM) program significantly improved patient's clinical outcomes and health-related quality of life (HRQOL) in a Latino/Hispanic-American community.
DESIGN: Quasi-experimental time-series study. SETTINGS: The study was implemented at two primary-care clinics in health maintenance organizations and two community pharmacy settings located in South Florida. PARTICIPANTS: Patients who have a long-term history of uncontrolled hypertension were identified and referred by their primary care physicians. INTERVENTION: A nine-month, community pharmacy-based hypertension disease-management program. MAIN OUTCOME MEASURES: HRQOL was assessed via SF-12 questionnaire and analyzed by norm-based scoring methods. Wilcoxon signed rank tests with 0.05 alpha levels were used to compare the differences in systolic blood pressure (SBP)/diastolic BP (DBP), medication compliance, and frequency of BP screenings between baseline and endpoint of the intervention.
RESULTS: A total of 53 patients (50.5%) completed the program. SBP/DBP significantly declined from 150.5/95.5 mmHg to 133.8/83.3 mmHg on the second month and remained consistent throughout the study period. Quality of life and mental component summary/physical component summary scores slightly increased from 48.58/46.68 to 50.39/51.51. The number of patients monitoring BP at home and medication compliance also significantly increased after nine months of intervention.
CONCLUSIONS: The key factor in accomplishing this DM program is meeting the health care needs of a unique population-the Hispanic-American community. Clinicians, administrators, and public health officials should note that understanding the broad parameters of a culture is essential to providing quality care to individuals, families, and communities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17658958     DOI: 10.4140/tcp.n.2007.411

Source DB:  PubMed          Journal:  Consult Pharm        ISSN: 0888-5109


  7 in total

1.  Improving actions to control high blood pressure in Hispanic communities - Racial and Ethnic Approaches to Community Health Across the U.S. Project, 2009-2012.

Authors:  Youlian Liao; Paul Z Siegel; Shannon White; Rick Dulin; April Taylor
Journal:  Prev Med       Date:  2015-12-04       Impact factor: 4.018

Review 2.  Interventions to increase medication adherence in African-American and Latino populations: a literature review.

Authors:  Daniel Hu; Deborah Taira Juarez; Michelle Yeboah; Theresa P Castillo
Journal:  Hawaii J Med Public Health       Date:  2014-01

3.  A Systems-Level Approach to Improving Medication Adherence in Hypertensive Latinos: a Randomized Control Trial.

Authors:  Antoinette Schoenthaler; Franzenith de la Calle; Maria Pitaro; Audrey Lum; William Chaplin; Jazmin Mogavero; Milagros C Rosal
Journal:  J Gen Intern Med       Date:  2019-10-17       Impact factor: 5.128

4.  Pharmacist intervention program to enhance hypertension control: a randomised controlled trial.

Authors:  Manuel Morgado; Sandra Rolo; Miguel Castelo-Branco
Journal:  Int J Clin Pharm       Date:  2011-01-13

5.  A practice-based randomized controlled trial to improve medication adherence among Latinos with hypertension: study protocol for a randomized controlled trial.

Authors:  Antoinette Schoenthaler; Franzenith De La Calle; Miguel Barrios-Barrios; Aury Garcia; Maria Pitaro; Audrey Lum; Milagros Rosal
Journal:  Trials       Date:  2015-07-02       Impact factor: 2.279

6.  Adherence: a review of education, research, practice, and policy in the United States.

Authors:  Nathaniel M Rickles; Todd A Brown; Melissa S Mcgivney; Margie E Snyder; Kelsey A White
Journal:  Pharm Pract (Granada)       Date:  2010-03-15

7.  A Project to Promote Adherence to Blood Pressure Medication Among People Who Use Community Pharmacies in Rural Montana, 2014-2016.

Authors:  Carrie S Oser; Crystelle C Fogle; James A Bennett
Journal:  Prev Chronic Dis       Date:  2017-06-29       Impact factor: 2.830

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.